Selective targeting of lysyl oxidase-like 2 (LOXL2) suppresses hepatic fibrosis progression and accelerates its reversal

Background/AimsWe studied the role of lysyl oxidase-like 2 (LOXL2) in collagen crosslinking and hepatic progenitor cell (HPC) differentiation, and the therapeutic efficacy of a LOXL2-blocking monoclonal antibody on liver fibrosis progression/reversal in mice.MethodsAnti-LOXL2 antibody, control antil...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Gut 2017-09, Vol.66 (9), p.1697-1708
Hauptverfasser:	Ikenaga, Naoki, Peng, Zhen-Wei, Vaid, Kahini A, Liu, Susan B, Yoshida, Shuhei, Sverdlov, Deanna Y, Mikels-Vigdal, Amanda, Smith, Victoria, Schuppan, Detlef, Popov, Yury V
Format:	Artikel
Sprache:	eng
Schlagworte:	Amino Acid Oxidoreductases - antagonists & inhibitors Animal models Animals Antibodies, Monoclonal - pharmacology Bile Cell Differentiation - drug effects Cell lineage Collagen Collagen - metabolism Disease Models, Animal Disease Progression Enzymes Fibrosis Gastroenterology Growth factors Hepatitis Hepatocytes Hepatocytes - physiology Hepatology Hypertension Liver cancer Liver Cirrhosis - drug therapy Liver Cirrhosis - pathology Liver Cirrhosis - physiopathology Liver diseases Lysyl oxidase Mice Mice, Inbred BALB C Molecular Targeted Therapy - methods Monoclonal antibodies Progenitor cells Recovery of Function - drug effects Rodents Septum Stem Cells - physiology Thioacetamide
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!